fixed or mixed effects model [BE/BA News]

posted by BEQool  – 2024-09-10 09:35 (255 d 07:03 ago) – Posting: # 24196
Views: 4,896

Hello Helmut,

thank you for the answers.
I just wanted to point out that, if I understand correctly, in ICH M13A basically nothing changes (PE and 90%CI) compared to EMA guideline on how to perform an analysis when periods are missing (because subject is a fixed factor) but compared to FDA guideline (subject as a random factor) PE and 90% CI change a little because now subjects with missing periods have to be excluded from the analysis (and according to FDA guideline you shouldnt exclude them)?

❝ P.S.: I modified the script in such a way that you can specify the number of dropouts and subjects with missings. Try this:

   CV         <- 0.15

   theta0     <- 0.975

   target     <- 0.90

   alpha      <- 0.05

   per.effect <- 0

   carryover  <- c(0, 0)

   dropouts   <- 2

   missings   <- 1

❝ Interesting, isn’t it?


Thanks, interesting indeed :ok:

Regards
BEQool

Complete thread:

UA Flag
Activity
 Admin contact
23,424 posts in 4,927 threads, 1,681 registered users;
50 visitors (0 registered, 50 guests [including 32 identified bots]).
Forum time: 16:38 CEST (Europe/Vienna)

Pharmacokinetics may be simply defined as
what the body does to the drug,
as opposed to pharmacodynamics, which may be defined as
what the drug does to the body.    Leslie Z. Benet

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5